Completed

This open label study was performed to assess the safety and tolerability of the EryDex System in people with A-T.

These trials studied whether a low dose betamethasone would reduce neurological symptoms associated with A-T.

This trial was performed to see if amantadine sulphate improves ataxia or other movement disorders associated with A-T.

Among the 204 identified CSF proteins, 13 showed significant changes in A-T patients versus control samples.

Two laboratory markers of oxidative stress improved when participants took both alpha-lipoic acid and nicotinamide.

No overall consistent improvement in neurologic function was observed on L-Dopa.

This trial in the Netherlands looked at the effects of nicotinamide ribose as a potential treatment for people with A-T.

Participants with A-T demonstrated lower brain activity or metabolism in the cerebellum as compared to control participants.

At the dose tested, Baclofen did not have a significant effect on tremor, eye movement or balance deficits.

This trial assessed the safety and efficacy of the EryDex System to treat neurological symptoms associated with A-T.